New hope for kids with severe colitis: drug shows promise in small trial
NCT ID NCT01585155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called TA-650 in 21 children with moderate to severe ulcerative colitis, a condition causing inflammation and sores in the colon. The goal was to see if the drug could reduce disease activity and improve symptoms. Children received the drug by infusion at several time points over 22 weeks, and doctors measured changes using a clinical activity index. The study focused on controlling the disease rather than curing it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Hokuriku, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kinki, Japan
-
Investigational site
Kyusyu, Japan
-
Investigational site
Tōhoku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?